Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Selective Expression Rather than Specific Function of Txk and Itk Regulate Th1 and Th2 Responses

(2014) N. Sahu et al.   JOURNAL OF IMMUNOLOGY

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Itk signalling in the interaction between influenza A virus and T-cells

(2012) K. Fan et al.   JOURNAL OF GENERAL VIROLOGY

Abbott boosts investment in NRF2 activators for reducing oxidative stress

(2012) Sarah Crunkhorn   NATURE REVIEWS DRUG DISCOVERY

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK

(2011) Alamdar Hussain et al.   FEBS Journal

Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates

(2011) Julio Gomez-Rodriguez et al.   FEBS Journal

Enhanced Chromatin Accessibility and Recruitment of JUNB Mediate the Sustained IL-4 Expression in NFAT1 Deficient T Helper 2 Cells

(2011) Jun-Seock Son et al.   PLoS One

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

(2010) Vicki A. Morrison   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Itk inhibitors: a patent review

(2010) Ho Yin Lo   EXPERT OPINION ON THERAPEUTIC PATENTS

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

(2009) D. I. Marks et al.   BLOOD

The Immune System and Cancer

(2009) David Loose et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Circumventing Immune Tolerance Through Epigenetic Modification

(2009) Jason Dubovsky et al.   CURRENT PHARMACEUTICAL DESIGN

Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses

(2009) Elizabeth Forbes et al.   IMMUNOLOGY AND CELL BIOLOGY

Selective targeting of ITK blocks multiple steps of HIV replication

(2008) J. A. Readinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA